AbbVie (ABBV) Hits New 52-Week High; Stock Up 40% Yearly
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowAbbVie (ABBV) reached a new 52-week high, marking a 40% increase over the past year. Year-to-date, the stock has risen approximately 11%, outperforming the S&P 500's 8% gain. AbbVie trades at less than 18 times its estimated future earnings, below the S&P 500 average of 21. The company recently announced a $10.9 billion acquisition of Apogee Therapeutics, which will enhance its immunology portfolio, suggesting long-term growth potential amidst a strong earnings performance.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About AbbVie Inc. (ABBV)
AbbVie is a research-based pharmaceutical company with a portfolio spanning immunology, oncology, and neuroscience.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABBV news
- AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug
- AbbVie (ABBV) Acquires Apogee for $10.9 Billion in Immunology Deal
- Dividend Portfolio Return: $43,770 Annual Income and $7,515 Tax Impact
- Johnson & Johnson (JNJ) Q1 2026 Revenue Hits $24.06 Billion
- AbbVie (ABBV) Q3 Earnings Beat Estimates on Immunology Drug Sales
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
